Cambridge Healthtech Institute’s 6th Annual

CAR Ts, TCRs and TILs

Latest Innovations and Developments in Adoptive Cell Therapy



Novel gene editing technologies and a greater understanding of cancer biology could unleash the full power of CAR T in both blood and solid tumors. But which therapies will succeed?

Cambridge Healthtech Institute’s Sixth Annual CARTs, TCRs and TILs conference focuses on the latest research, protein engineering and clinical strategies driving the development of adoptive cell therapies across a wide range of indications. Clinical progress with Chimeric Antigen Receptors (CAR), T Cell Receptors (TCR), Tumor Infiltrating Lymphocytes (TIL), and NK cells will be addressed and new strategies for commercialization will be reviewed.

Coverage will include, but is not limited to:


  • New understandings of T cell receptors – turning cold tumors hot
  • Understanding the mechanism of treatment failure
  • Progress in:
    • Chimeric Antigen Receptors (CAR), including gene edited CAR Ts
    • Tandem CARs
    • T Cell Receptors (TCR)
    • Tumor Infiltrating Lymphocytes (TIL)
    • Next-generation CAR Ts
  • Other subtypes
    • NK Cells
    • TRegs
    • Gamma Deltas
  • Potential of “off the shelf” therapies
  • Impact of gene editing
  • Combination therapies – results and challenges
  • Developing immunotherapies for solid tumors – progress
  • Manipulating the tumor microenvironment
  • Approaches to target discovery
    • Genetic targets
    • Patient and tumor specific targets
    • Neoepitopes
  • Currently targeted antigens and new antigens under investigation
  • Developability and manufacturing challenges and solutions for scale-up 

* 活动内容有可能不事先告知作更动及调整。

Choose your language